Gerresheimer, a manufacturer of special glass and plastic products to the pharmaceutical industry, has agreed to acquire Sensile Medical AG, an Olten, Switzerland-based medical technology company, in a deal worth up to €350 million (depending on the achievement of contractually specified milestones).

Gerresheimer says it is extending its business model in the direction of an original equipment manufacturer (OEM) for drug-delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers. Sensile Medical develops drug-delivery products and platforms, including digital connected capabilities. It is working with customers on developing devices for diabetics and patients with heart complaints. Going forward, it is planned that Sensile Medical will function as the Development Center for Value-Added Devices within Gerresheimer.

Independently of this, Gerresheimer reports that it has secured two new contracts: one for manufacturing inhalers and another for prefillable syringes for a heparin producer. At the same time, Gerresheimer reports that it has lost a smaller order in its inhaler business, resulting in a restructuring that will affect the company’s plant in Küssnacht, Switzerland, which is scheduled to be closed by the end of 2019.